Holen Sie sich die Stockscreener-App
42.38
0.47%
0.20
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo! Finance Canada
Sage Therapeutics stock exits public markets after Supernus deal - AD HOC NEWS
Indivior stock: company declares conditional USD 8.13 special dividend - AD HOC NEWS
Is Supernus Pharmaceuticals Inc (SUPN) Overvalued After 4.5% Ral - GuruFocus
Supernus Pharmaceuticals, Inc. (SUPN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.SUPN - Business Wire
Supernus Pharmaceuticals, Inc. (SUPN) Stock forecasts - uk.finance.yahoo.com
Supernus Pharmaceuticals (SUPN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Liquidity Mapping Around (SUPN) Price Events - Stock Traders Daily
Supernus, Indivior get early termination of US waiting period - MLex
3 Reasons SUPN is Risky and 1 Stock to Buy Instead - theglobeandmail.com
Why Did Supernus Pharmaceuticals (SUPN) Move Today? - Yahoo Finance
How Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ Outlook - Yahoo Finance
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Shares Surge 3.6% -- What GF Score of 87 Tells Investors - GuruFocus
Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger - Yahoo Finance
An $8.13 cash payout at Indivior (INDV) hinges on a merger closing - Stock Titan
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend - Indivior
Discipline and Rules-Based Execution in SUPN Response - Stock Traders Daily
$1 billion dividend hangs on Supernus (NASDAQ: SUPN) merger vote - Stock Titan
Supernus at Wells Fargo conference: growth after patent losses By Investing.com - Investing.com Canada
Supernus at Wells Fargo conference: growth after patent losses - Investing.com
Indivior stock gains as Supernus merger and special dividend plan come into focus - AD HOC NEWS
Supernus at cantor global healthcare conference: merger and growth push By Investing.com - Investing.com Nigeria
Indivior (INDV) plans special dividend if Supernus merger closes, with two payout structures - Stock Titan
SUPN: Strong CNS portfolio growth and a strategic merger position the company for accelerated innovation - TradingView
Supernus Pharmaceuticals stock hits 52-week low at 42.39 USD By Investing.com - Investing.com Nigeria
Supernus Pharmaceuticals stock hits 52-week low at 42.39 USD - investing.com
Indivior stock gains on raised 2026 guidance and Supernus deal - ad-hoc-news.de
SUPN Stock Price, Quote & Chart - ChartMill
Supernus Pharmaceuticals Inc. (SUPN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Supernus Pharmaceuticals to Participate in September Investor Conferences - The Manila Times
Supernus Pharmaceuticals Inc. (SUPN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD - Yahoo Finance
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded - GlobeNewswire
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - barchart.com
Supernus Pharmaceuticals Inc. (SUPN) Peer Comparison – Compare with Others - Value Research
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Super - The National Law Review
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - FinancialContent
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock? - TradingView
A Look at Supernus Pharmaceuticals Inc (SUPN) After 3.4% Decline -- GF Value $43.78 vs Price $45.85 - GuruFocus
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Barchart.com
25,400 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Mystic Asset Management Inc. - MarketBeat
Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal - AD HOC NEWS
Supernus Pharmaceuticals (SUPN) Stock Looks Reasonable On Sales While Returns Look Strong - Sahm
1.15%
5.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):